Michels S, Messmer E, Sutter F, Kurz-Levin M M
Ophthalmology, University Hospital Zurich.
Klin Monbl Augenheilkd. 2008 Apr;225(4):292-4. doi: 10.1055/s-2008-1027175.
Up-regulated expression of the vascular endothelial growth factor (VEGF) in von Hippel-Lindau (VHL) disease has been postulated to induce retinal hemangioblastoma. Intravitreal injections of anti-VEGF drugs might provide a new therapeutic option in this condition.
In a single case decision a patient with active retinal hemangioblastomas due to VHL disease received repeated intravitreal injections of 0.5 mg ranibizumab.
Subsequent to intravitreal anti-VEGF therapy, the signs of activity of the retinal hemangioblastomas slowly regressed.
Intravitreal anti-VEGF therapy might, as monotherapy or as combination therapy, offer a new treatment option for retinal hemangioblastoma.
血管内皮生长因子（VEGF）在冯·希佩尔-林道（VHL）病中的表达上调被认为可诱导视网膜血管瘤。玻璃体内注射抗VEGF药物可能为这种情况提供一种新的治疗选择。
在一个单病例决策中，一名因VHL病患有活动性视网膜血管瘤的患者接受了多次0.5毫克雷珠单抗的玻璃体内注射。
玻璃体内抗VEGF治疗后，视网膜血管瘤的活动迹象逐渐消退。
玻璃体内抗VEGF治疗作为单一疗法或联合疗法，可能为视网膜血管瘤提供一种新的治疗选择。
